{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:01:57Z","timestamp":1789012917333,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To explore the efficacy and safety of L-asparaginase in newly-diagnosed extranodal nature killer (NK)\/T \u2013cell lymphoma (ENKTL), we conducted a prospective phase II study of L-asparaginase, cyclophosphamide, vincristine, doxorubicin and dexamethasone (CHOP-L) regimen in combination with radiotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Patients with newly diagnosed ENKTL and an ECOG performance status of 0 to 2 were eligible for enrollment. Treatment included 6\u20138\u00a0cycles of CHOP-L (cyclophosphamide, 750\u00a0mg\/m<jats:sup>2<\/jats:sup>\u00a0day 1; vincristine, 1.4\u00a0mg\/m<jats:sup>2<\/jats:sup>\u00a0day 1 (maximal dose 2\u00a0mg), doxorubicin 50\u00a0mg\/m<jats:sup>2<\/jats:sup>\u00a0day 1; dexamethasone 10\u00a0mg\u00a0days 1\u20138; L-asparaginase 6000 u\/m<jats:sup>2<\/jats:sup>\u00a0days 2\u20138). Radiotherapy was scheduled after 4\u20136\u00a0cycles of CHOP-L regimen, depending on stage and primary anatomic site. The primary endpoint was complete response (CR) rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 38 eligible patients were enrolled. The median age was 40.5\u00a0years (range, 15 to 71\u00a0years). Their clinical characteristics were male to female ratio, 24:14; Ann Arbor stage I, 20; II, 11; III, 3; IV, 4. CR and overall response rates were 81.6% (95% CI, 69.3% to 93.9%) and 84.2%, respectively. With a median follow-up of 25\u00a0months, the 2-year overall survival, progression-free survival and disease-free survival rates were 80.1% (95%CI, 73.3% to 86.9%), 81% (95%CI, 74.5% to 87.5%) and 93.6% (95%CI, 89.3% to 97.9%), respectively. The major adverse events were myelosuppression, liver dysfunction, and digestive tract toxicities. Grade 3 to 4 leukopenia and neutropenia were 76.3% and 84.2%, respectively. No treatment-related death was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CHOP-L chemotherapy in combination with radiotherapy is a safe and highly effective treatment for newly diagnosed ENKTL.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1756-8722-6-44","type":"journal-article","created":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T12:14:45Z","timestamp":1372680885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK\/T-cell lymphoma, nasal type"],"prefix":"10.1186","volume":"6","author":[{"given":"Ningjing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifeng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,1]]},"reference":[{"issue":"4","key":"323_CR1","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1365-2141.2007.06835.x","volume":"139","author":"K Oshimi","year":"2007","unstructured":"Oshimi K: Progress in understanding and managing natural killer-cell malignancies. Br J Haematol. 2007, 139 (4): 532-544. 10.1111\/j.1365-2141.2007.06835.x.","journal-title":"Br J Haematol"},{"issue":"2","key":"323_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hon.847","volume":"26","author":"R Suzuki","year":"2008","unstructured":"Suzuki R, Takeuchi K, Ohshima K, Nakamura S: Extranodal NK\/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol. 2008, 26 (2): 66-72. 10.1002\/hon.847.","journal-title":"Hematol Oncol"},{"issue":"3","key":"323_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C: Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012, 138 (3): 429-434. 10.1309\/AJCP7YLTQPUSDQ5C.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"323_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-5-24","volume":"5","author":"S Jain","year":"2012","unstructured":"Jain S, Zain J, O'Connor O: Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol. 2012, 5 (1): 24-10.1186\/1756-8722-5-24.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"323_CR5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0609.2007.00978.x","volume":"80","author":"ST Lim","year":"2008","unstructured":"Lim ST, Hee SW, Quek R, Lim LC, Yap SP, Loong EL, Sng I, Tan LH, Ang MK, Ngeow J: Comparative analysis of extra-nodal NK\/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. Eur J Haematol. 2008, 80 (1): 55-60.","journal-title":"Eur J Haematol"},{"issue":"1","key":"323_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.2000.18.1.54","volume":"18","author":"GE Kim","year":"2000","unstructured":"Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, Hong WP, Park IY, Hahn JS, Roh JK: Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000, 18 (1): 54-63.","journal-title":"J Clin Oncol"},{"issue":"1","key":"323_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","volume":"24","author":"YX Li","year":"2006","unstructured":"Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH: Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma. J Clin Oncol. 2006, 24 (1): 181-189. 10.1200\/JCO.2005.03.2573.","journal-title":"J Clin Oncol"},{"issue":"4","key":"323_CR8","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ijrobp.2003.12.006","volume":"59","author":"WS Koom","year":"2004","unstructured":"Koom WS, Chung EJ, Yang WI, Shim SJ, Suh CO, Roh JK, Yoon JH, Kim GE: Angiocentric T-cell and NK\/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004, 59 (4): 1127-1137. 10.1016\/j.ijrobp.2003.12.006.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"323_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/cncr.21656","volume":"106","author":"K Isobe","year":"2006","unstructured":"Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, Okada J, Itami J, Ito H: Extranodal natural killer\/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer. 2006, 106 (3): 609-615. 10.1002\/cncr.21656.","journal-title":"Cancer"},{"issue":"7","key":"323_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00277-008-0669-3","volume":"88","author":"W Yong","year":"2009","unstructured":"Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J: L-asparaginase in the treatment of refractory and relapsed extranodal NK\/T-cell lymphoma, nasal type. Ann Hematol. 2009, 88 (7): 647-652. 10.1007\/s00277-008-0669-3.","journal-title":"Ann Hematol"},{"issue":"1","key":"323_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/annonc\/mdn542","volume":"20","author":"A Jaccard","year":"2009","unstructured":"Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thieblemont C: L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009, 20 (1): 110-116.","journal-title":"Ann Oncol"},{"issue":"4","key":"323_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF02982090","volume":"74","author":"K Nagafuji","year":"2001","unstructured":"Nagafuji K, Fujisaki T, Arima F, Ohshima K: L-asparaginase induced durable remission of relapsed nasal NK\/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol. 2001, 74 (4): 447-450. 10.1007\/BF02982090.","journal-title":"Int J Hematol"},{"issue":"3","key":"323_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/BF02983802","volume":"78","author":"K Obama","year":"2003","unstructured":"Obama K, Tara M, Niina K: L-asparaginase-Based induction therapy for advanced extranodal NK\/T-cell lymphoma. Int J Hematol. 2003, 78 (3): 248-250. 10.1007\/BF02983802.","journal-title":"Int J Hematol"},{"issue":"11","key":"323_CR14","first-page":"577","volume":"21","author":"W Yong","year":"2000","unstructured":"Yong W, Zhang Y, Zheng W: The efficacy of L-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2000, 21 (11): 577-579.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"13","key":"323_CR15","first-page":"773","volume":"81","author":"W Yong","year":"2001","unstructured":"Yong W, Zheng W, Zhang Y: Clinical characteristics and treatment of midline nasal and nasal type NK\/T cell lymphoma. Zhonghua Yi Xue Za Zhi. 2001, 81 (13): 773-775.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"2","key":"323_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF02983387","volume":"78","author":"W Yong","year":"2003","unstructured":"Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J: L-asparaginase-based regimen in the treatment of refractory midline nasal\/nasal-type T\/NK-cell lymphoma. Int J Hematol. 2003, 78 (2): 163-167. 10.1007\/BF02983387.","journal-title":"Int J Hematol"},{"issue":"1","key":"323_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hon.765","volume":"24","author":"W Yong","year":"2006","unstructured":"Yong W, Zheng W, Zhu J, Zhang Y, Wei Y, Wang X, Lin N, Xie Y, Xu B, Li J: Midline NK\/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol. 2006, 24 (1): 28-32. 10.1002\/hon.765.","journal-title":"Hematol Oncol"},{"issue":"6","key":"323_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","volume":"117","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L: Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study. Blood. 2011, 117 (6): 1834-1839. 10.1182\/blood-2010-09-307454.","journal-title":"Blood"},{"issue":"33","key":"323_CR19","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011, 29 (33): 4410-4416. 10.1200\/JCO.2011.35.6287.","journal-title":"J Clin Oncol"},{"issue":"5","key":"323_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/CCO.0b013e328349aba6","volume":"23","author":"A Jaccard","year":"2011","unstructured":"Jaccard A, Hermine O: Extranodal natural killer\/T-cell lymphoma: advances in the management. Curr Opin Oncol. 2011, 23 (5): 429-435. 10.1097\/CCO.0b013e328349aba6.","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"323_CR21","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s12185-012-1189-4","volume":"96","author":"M Yamaguchi","year":"2012","unstructured":"Yamaguchi M: Current and future management of NK\/T-cell lymphoma based on clinical trials. Int J Hematol. 2012, 96 (5): 562-571. 10.1007\/s12185-012-1189-4.","journal-title":"Int J Hematol"},{"issue":"7","key":"323_CR22","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1182\/blood-2002-06-1901","volume":"101","author":"U Nowak-Gottl","year":"2003","unstructured":"Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C, Junker R: Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003, 101 (7): 2529-2533. 10.1182\/blood-2002-06-1901.","journal-title":"Blood"},{"key":"323_CR23","first-page":"285","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"JKC Chan","year":"2008","unstructured":"Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC: Extranodal NK\/T- cell lymphoma, nasal type. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008, Lyon, France: IARC PRESS, 285-288. 4","edition":"4"},{"issue":"12","key":"323_CR24","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/j.1349-7006.2009.01319.x","volume":"100","author":"TM Kim","year":"2009","unstructured":"Kim TM, Heo DS: Extranodal NK \/ T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009, 100 (12): 2242-2248. 10.1111\/j.1349-7006.2009.01319.x.","journal-title":"Cancer Sci"},{"issue":"10","key":"323_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.ejca.2005.03.010","volume":"41","author":"J Lee","year":"2005","unstructured":"Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH: Extranodal nasal type NK\/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005, 41 (10): 1402-1408. 10.1016\/j.ejca.2005.03.010.","journal-title":"Eur J Cancer"},{"issue":"5","key":"323_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E: Revised response criteria for malignant lymphoma. J Clin Oncol. 2007, 25 (5): 579-586. 10.1200\/JCO.2006.09.2403.","journal-title":"J Clin Oncol"},{"issue":"4","key":"323_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS: Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006, 24 (4): 612-618. 10.1200\/JCO.2005.04.1384.","journal-title":"J Clin Oncol"},{"issue":"35","key":"323_CR28","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","volume":"27","author":"SJ Kim","year":"2009","unstructured":"Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW: Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol. 2009, 27 (35): 6027-6032. 10.1200\/JCO.2009.23.8592.","journal-title":"J Clin Oncol"},{"issue":"33","key":"323_CR29","doi-asserted-by":"publisher","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","volume":"27","author":"M Yamaguchi","year":"2009","unstructured":"Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N: Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009, 27 (33): 5594-5600. 10.1200\/JCO.2009.23.8295.","journal-title":"J Clin Oncol"},{"issue":"3","key":"323_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0167-8140(01)00428-5","volume":"61","author":"GE Kim","year":"2001","unstructured":"Kim GE, Lee SW, Chang SK, Park HC, Pyo HR, Kim JH, Moon SR, Lee HS, Choi EC, Kim KM: Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol. 2001, 61 (3): 261-269. 10.1016\/S0167-8140(01)00428-5.","journal-title":"Radiother Oncol"},{"issue":"17","key":"323_CR31","doi-asserted-by":"publisher","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","volume":"113","author":"WY Au","year":"2009","unstructured":"Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R: Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009, 113 (17): 3931-3937. 10.1182\/blood-2008-10-185256.","journal-title":"Blood"},{"issue":"2","key":"323_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/cncr.11908","volume":"100","author":"CC Li","year":"2004","unstructured":"Li CC, Tien HF, Tang JL, Yao M, Chen YC, Su IJ, Hsu SM, Hong RL: Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer\/T-cell or T-cell lymphoma. Cancer. 2004, 100 (2): 366-375. 10.1002\/cncr.11908.","journal-title":"Cancer"},{"issue":"15","key":"323_CR33","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS: SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012, 120 (15): 2973-2980. 10.1182\/blood-2012-05-431460.","journal-title":"Blood"},{"issue":"7","key":"323_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","volume":"115","author":"LB Silverman","year":"2010","unstructured":"Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD: Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010, 115 (7): 1351-1353. 10.1182\/blood-2009-09-245951.","journal-title":"Blood"},{"issue":"6","key":"323_CR35","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002, 99 (6): 1986-1994. 10.1182\/blood.V99.6.1986.","journal-title":"Blood"},{"issue":"1","key":"323_CR36","first-page":"29","volume":"29","author":"The Cooperation Group of Phase II Clinical Trial of PEG-Asp","year":"2008","unstructured":"The Cooperation Group of Phase II Clinical Trial of PEG-Asp: Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2008, 29 (1): 29-33.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"323_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1756-8722-5-27","volume":"5","author":"A Chauchet","year":"2012","unstructured":"Chauchet A, Michallet A-S, Berger F, Bedgedjian I, Deconinck E, Sebban C, Antal D, Orfeuvre H, Corront B, Petrella T: Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK\/T cell lymphoma. J Hematol Oncol. 2012, 5 (1): 27-10.1186\/1756-8722-5-27.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"323_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1756-8722-4-34","volume":"4","author":"YR Kim","year":"2011","unstructured":"Kim YR, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. J Hematol Oncol. 2011, 4 (1): 34-10.1186\/1756-8722-4-34.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"323_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004, 104 (3): 626-633. 10.1182\/blood-2003-06-2094.","journal-title":"Blood"},{"issue":"1","key":"323_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1756-8722-5-51","volume":"5","author":"X Jin","year":"2012","unstructured":"Jin X, Ding H, Ding N, Fu Z, Song Y, Zhu J: Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP. J Hematol Oncol. 2012, 5 (1): 51-10.1186\/1756-8722-5-51.","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-8722-6-44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T13:04:06Z","timestamp":1715605446000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/1756-8722-6-44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1186\/1756-8722-6-44","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,1]]},"assertion":[{"value":"30 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"44"}}